[Pharmacokinetic and clinical studies on teicoplanin for sepsis by methicillin-cephem resistant Staphylococcus aureus in the pediatric and neonate field]
Keisuke Sunakawa,Masato Nonoyama,Ryochi Fujii,Naoichi Iwai,Hiroshi Sakata,Masaru Shirai,Takashi Sato,Mayumi Kajino,Yoshikiyo Toyonaga,Tomoaki Sano,Atsushi Naito,Kimio Minagawa,Yuichi Niida,Takanori Oda,Masato Yokozawa,Hideomi Asanuma,Kohji Shimura,Masanori Fujimura,Hiroyuki Kitajima,Katsura Fujinami,Kei Numazaki,Tomoko Fujikawa,Yutaka Kobayashi,Yoshitake Sato,Tadafumi Nishimura,Satoshi Iwata,Nihoko Tsuchihashi,Tomohiro Oishi,Shinji Matsumoto,Takashi Motohiro,Makiko Osawa,Mariko Sunahara,Seigo Shirakawa,Hiroshi Nishida,Naoto Takahashi,Reiji Nakano,Nobuaki Sai,Kuniaki Iyoda,Kazunori Yoshimitsu,Kazunori Ogawa,Tomio Okazaki,Ichiro Tsukimoto,Osamu Motoyama,Yoshiteru Takada,Masahiro Kawasaki,Wataru Sunaoshi,Shinya Nakamura,Yasuhisa Ueda,Masahiro Kamata,Tatsuo Kato,Mitsuo Chiba,Kazunobu Ouchi,Shiro Sato,Takeshi Horiuchi,Keiji Suzuki,Takenori Shimoyama,Hiroshi Masaki,Miho Aikyo,Momoko Kawada,Masahiro Banba,Seikyo Furukawa,Takashige Okada,Satoru Yamaguchi,Osamu Hirota,Shoichi Koizumi,Hideo Wada,Kazuhide Ohta,Takahiro Uehara,Ko Yukitake,Toshiko Mori,Satoshi Takakuwa,Kenji Matsuyama
Abstract:Pharmacokinetics, clinical efficacy and safety of teicoplanin (TEIC) were evaluated in pediatric and neonate patients with MRSA sepsis in the dosages approved in overseas. The administrated dose for pediatrics patients was 10 mg/kg once at hour 0, 12 and 24, followed by every 24 hours intervals. In neonates patients, first dose was 16 mg/kg, then 8 mg/kg every 24 hours intervals. 1. Pharmacokinetic results. All 17 patients (9 neonates and 8 pediatrics) who received TEIC were evaluated for pharmacokinetics. Trough concentrations were analyzed in 16 patients (9 neonates and 7 pediatrics) excluding one patient for lack of measurement of drug concentration at day 7. No patient with a concentration exceeding 60 micrograms/mL in peak or trough concentrations were reported. Mean concentrations in trough at day 3, 4 and 7 in neonates were 15.2, 14.7 and 17.8 micrograms/mL, and in pediatrics were 12.5, 12.2 and 13.1 micrograms/mL, respectively. These results were similar to those reported in foreign pediatrics and neonates patients. 2. Efficacy and safety results. Since no patient was excluded, all patients were evaluated for efficacy and safety. Microbiological efficacy as well as clinical cure were secondarily evaluated in 2 patients for whom MRSA was isolated from blood. Clinical efficacy rate was 76.5% (13/17) and number of cases in judgments of excellent, good, fairly improved and no change were 12, 1, 3 and 1 cases respectively. The patients for whom MRSA was isolated from blood were judged as MRSA eradicated case and cured without any additional anti-MRSA drugs. Adverse events were reported in 2 neonates and 3 pediatric patients. Possibly related adverse events to study drug (adverse drug reactions) were: 1 case of respiratory disorder, thrombocythemia, gamma-GTP increased, GOT increased and GPT increased in 3 pediatrics. These results suggest that an application of overseas dose regimen of TEIC for neonate and pediatrics is appropriate in Japan.